Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Firas Hassan
Total Records ( 2 ) for Firas Hassan
  Firas Hassan , Ayah Abdul Hameed , Ahemd Alshanon , Bashar Mudhaffar Abdullah , Hasniza Zaman Huri , Nany Hairunisa and Emad Yousif
  Multipara metric analysis of compound toxicity at the level of individual cells using flow cytometry and cellular imaging-based approaches such as High Content Screening (HCS) have played key roles in the detection of toxicity and classification of compounds based on observed patterns of reversible and irreversible cellular injury. Gold III complex (AuL2) of bidentate ligand derived from the cyclization reaction of Schiff base of 4-amino-5-phenyl-4h-1,2,4-triazole-3-thiol with thioglycolic acid was synthesized and characterized by using melting point, FTIR spectroscopy, 1HNMR, UV-Visible spectroscopy and elemental analysis. The presence of chloride counter ion in complex was supported by conductivity measurement and the presence of hydrated water was supported by thermal gravimetric studies. We examine the cytotoxic effects of gold complex and its ligand in one cultured cellular models (MCF7 cell line) by High Content Screening (HCS) and analysis and cell viability assay (MMT assay). The inhibitory effect of AuL2 on breast cancer cell growth was due to induction of apoptosis as evidenced by annexin V staining and cell shrinkage. The study found that AuL2-mediated lead to disruption of Mitochondrial Membrane Potential (MMP), cell membrane permeability, nuclear condensation, fragmentation and release of cytochrome c from the mitochondria into the cytosol and also suggesting AuL2 as a potential MCF7 inhibitor compared to doxorubicin as positive control. In this study, data showed that gold (III) complex AuL2 may have therapeutic value in breast cancer treatment worthy of further development.
  Ali Z. Al-Saffar , Ahmed F. Al-Shanon , Shymaa L. Al-Brazanchi , Fatimah A. Sabry , Firas Hassan and Noora A. Hadi
  Background: Pelargonium graveolens is an important medicinal plant traditionally used to heal wounds, ulcers, skin disorders and diarrhea. Despite its well-known antioxidant activity, the cytotoxicity of P. graveolens crude extract has not been well documented. Methodology: Methanolic fraction was extracted from P. graveolens leaves and was analyzed by GC/MS. Two modes of experiments were performed: First, assessing antioxidant activity using DPPH free radicals, while the second, detecting the effect of the extract on MCF-7 cell morphology, viability, stress responses, mitochondrial potential and Reactive Oxygen Species (ROS) generation were examined with MTT and High Content Screening (HCS) scanning. Results: Twenty four compounds have been identified which constitute 90.02% of the extract. A dose-dependent reduction in DPPH was recorded with IC50 of 484 μg mL–1. The MTT results showed a dose-dependent anti-tumor activity and reduction in cell viability against MCF-7 cells with IC50 of 288 μg mL–1. Further examination of HCS results indicated a dose-dependently growth inhibition of MCF-7 cells (53.92% at 200 μg mL–1). Membrane permeability also increased in a dose-dependent manner, while only high concentrations caused alterations in nucleus morphology. A 40.3% reduction in the mitochondrial potential was observed. Such disruptions resulted in the release of cytochrome C, for which a 0.7 fold increase was detected in the treated MCF-7 cells compared with untreated cells. Treatment also resulted in a 0.53 and 1.32 folds increases in generation of ROS at 100 and 200 μg mL–1, respectively. Conclusion: Methanolic extract of P. graveolens exhibited a significant antioxidant activity and has profound cytotoxic activity against MCF-7 cell line.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility